Treatment modality and risk of development of dysplasia and adenocarcinoma in columnar-lined esophagus

Diseases of the Esophagus

Volumn 22, Issue 2, 2009, Pages 133-142

  Gatenby, Piers A C ^a   Ramus, James R ^a   Caygill, Christine P J ^a   Charlett, Andre ^b   Winslet, Marc C ^a   Watson, Anthony ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Antireflux surgery; Barrett's esophagus; Esophageal cancer; Gastro esophageal reflux disease; Proton pump inhibitors

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADULT; ANTIREFLUX OPERATION; CARCINOGENESIS; CLINICAL PROTOCOL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; METAPLASIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; UNITED KINGDOM;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; FUNDOPLICATION; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; METAPLASIA; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES;

EID: 60549091601     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2008.00886.x     Document Type: Review

References (66)

1. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
2. Parrilla P, Ortiz A, Martinez de Haro L F, Aguayo J L, Ramirez P. Evaluation of the magnitude of gastro-oesophageal reflux in Barrett's oesophagus. Gut 1990; 31: 964-7.
3. Avidan B, Sonnenberg A, Schnell T G, Chejfec G, Metz A, Sontag S J. Hiatal hernia size, Barrett's length and severity of acid reflux are all risk factors for oesophageal adenocarcinoma. Am J Gastroenterol 2002; 97: 1930-6.
4. Champion G, Richter J E, Vaezi M F, Singh S, Alexander R. Duodenogastroesophageal reflux: Relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994; 107: 747-54.
5. Stein H J, Feussner H, Kauer W, Demeester T R, Siewert J R. Alkaline gastroesophageal reflux: Assessment by ambulatory esophageal aspiration and pH monitoring. Am J Surg 1994; 167: 163-8.
6. Vaezi M F, Richter J E. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996; 111: 1192-9.
7. Lieberman D A, Oehlke M, Helfand M, the GORGE Consortium. Risk factors for Barrett's esophagus in community-based practice. Am J Gastroenterol 1997; 92: 1293-7.
8. Locke G R, Zinsmeister A R, Talley N J. Can symptoms predict endoscopic findings in GERD? Gastrointest Endosc 2003; 58: 661-70.
9. Sampliner R E, The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97: 1888-95.
10. Watson A, Heading R C, Shepherd N A. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus: A report of the working party of the British Society of gastroenterology. British Society of Gastroenterology; 2005, London, UK; 1-42.
11. Shepherd N A. Barrett's esophagus: Its pathology and neoplastic complications. Esophagus 2003; 1: 17-29.
12. Gatenby P A C, Ramus J R, Caygill C P J, Shepherd N A, Watson A. The relevance of detection of intestinal metaplasia in columnar-lined esophagus. Scand J Gastroenterol 2008.
13. van der Veen A H, Blankenstein J D, van Blankenstein M. Adenocarcinoma in Barrett's oesophagus: An overrated risk. Gut 1989; 30: 14-8.
14. Bartelsman J F W M, Hameeteman W, Tytgat G N. Barrett's oesophagus. Eur J Cancer Prev 1992; 1: 323-5.
15. Iftikar S Y, James P D, Steele R J C, Hardcastle J D, Atkinson M. Length of Barrett's oesophagus: An important factor in the development of dysplasia and adenocarcinoma. Gut 1992; 33: 1155-8.
16. Solaymani-Dodaran M, Logan R F A, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004; 53: 1070-4.
17. Anderson L A, Murray L J, Murphy S J et al. Mortality in Barrett's oesophagus: Results from a population based study. Gut 2003; 52: 1081-4.
18. Gatenby P A C, Caygill C P J, Ramus J R, Charlett A, Watson A. Barrett's columnar-lined oesophagus: Demographic associations and adenocarcinoma risk. Dig Dis Sci 2008; 53: 1175-85.
19. Lundell L, Miettinen P, Myrvold H E et al. Continued (5-year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001; 192: 172-9.
20. Katzka D A, Castell D O. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 989-91.
21. Sampliner R E. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 1994; 89: 1844-8.
22. Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalisation of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998; 93: 711-6.
23. Sharma P, Sampliner R E, Camargo E. Normalisation of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997; 92: 582-5.
24. McDonald M L, Trastek V F, Allen M S, Deschamps C, Pairolero P C. Barrett's esophagus: Does an antireflux procedure reduce the need for endoscopic surveillance. J Thorac Cardiovasc Surg 1996; 111: 1135-40.
25. Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998; 93: 536-41.
26. McCallum R W, Polepalle S C, Davenport K, Frierson H, Boyd S. Role of anti-reflux surgery against dysplasia in Barrett's esophagus. Gastroenterology 1991; 100: A121.
27. Microsoft Access, Version 10. 2002; 10.4302.42019.
28. Schlemper R J, Riddell R H, Kato Y et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-5.
29. SPSS for Windows, Version 11. 2001.
30. Caygill C P J, Reed P I, Johnston B J, Hill M J, Ali M H, Levi S. A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis. Eur J Gastroenterol Hepatol 1999; 11: 1355-8.
31. Caygill C P J, Reed P I, McIntyre A, Hill M J. The UK National Barrett's Oesophagus Registry: A study between two centres. Eur J Cancer Prev 1998; 7: 161-4.
32. Prach A T, MacDonald T A, Hopwood D A, Johnson D A. Increasing incidence of Barrett's oesophagus: Education, enthusiasm, or epidemiology. Lancet 1997; 350: 933.
33. Carton E, Caldwell M T P, McDonald G, Rama D, Tanner W A, Reynolds J V. Specialized intestinal metaplasia in patients with gastro-oesophageal reflux disease. Br J Surg 2000; 87: 116-21.
34. Cameron A J, Zinsmeister A R, Ballard D J. Prevalence of columnar-lined (Barrett's) esophagus: Comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99: 918-22.
35. Cameron A J. What is the prevalence of long segment Barrett's esophagus? In: Giuli R, Siewert J R, Couturier D, Scarpignato C (eds). Barrett's Esophagus. Esher, UK: John Libby Eurotext, 2003; 60-2.
36. Powell J, McConkey C E. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev 1992; 1: 265-9.
37. Byrne P J, Mathers J M, Parry J M, Attwood S E A, Bancewicz J, Woodman C B J. Site distribution of oesophagogastric cancer. J Clin Pathol 2002; 55: 191-4.
38. Johnston B J, Reed P I. Changing pattern of oesophageal cancer in a general hospital in the UK. Eur J Cancer Prev 1990; 1: 23-5.
39. McKinney P A, Sharp L, Macfarlane G J, Muir C S. Oesophageal and gastric cancer in Scotland 1960-90. Br J Cancer 1995; 71: 411-5.
40. Liabeuf A, Faivre J. Time trends in oesophageal cancer incidence in Cote d'Or (France), 1976-93. Eur J Cancer Prev 1997; 6: 24-30.
41. Moller H. Incidence of cancer of the oesophagus, cardia and stomach in Denmark. Eur J Cancer Prev 1992; 1: 159-64.
42. Hansen S, Wiig J N, Giercksky K E, Tretli S. Esophageal and gastric carcinoma in Norway 1958-1992: Incidence time trend variability according to morphological subtypes and organ subsites. Int J Cancer 1997; 71: 340.
43. Blot W J, Devesa S S, Kneiler R W, Fraumeni J F. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-9.
44. El-Serag H B, Mason A C, Petersen N, Key R C. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 2002; 50: 368-72.
45. Daly J M, Karnell L H, Menck H R. National cancer data base report on esophageal carcinoma. Cancer 1996; 78: 1820-8.
46. Chalasani N, Wo J M, Waring J P. Racial differences in the histology, location and risk factors of esophageal cancer. J Clin Gastroenterol 1998; 26: 11-3.
47. Armstrong R W, Borman B. Trends in incidence rates of adenocarcinoma of the oesophagus and gastric cardia in New Zealand 1978-92. Int J Epidemiol 1996; 25: 941-7.
48. Lord R V, Law M G, Ward R L, Giles G G, Thomas R J, Thursfield V. Rising incidence of oesophageal adenocarcinoma in men in Australia. J Gastroenterol Hepatol 1998; 13: 356-62.
49. Nietert P J, Silverstein M D, Makhashi M S etal. Cost-effectiveness of screening a population with chronic gastroesophageal reflux. Gastrointest Endosc 2003; 57: 311-8.
50. Eloubeidi M A, Homan R K, Martz M D, Theobald K E, Provenzale D. A cost analysis of outpatient care for patients with Barrett's esophagus in a managed care setting. Am J Gastroenterol 1999; 94: 2033-6.
51. Provenzale D, Schmitt C, Wong J B. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94: 2043-53.
52. Streitz J M, Ellis F H, Tilden R L, Erickson R V. Endoscopic surveillance of Barrett's esophagus: A cost-effectiveness comparison with mammogaphic surveillance for breast cancer. Am J Gastroenterol 1998; 93: 911-5.
53. Winters C Jr, Spurling T J, Chobanian S J et al. Barrett's esophagus: A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 118-24.
54. Csendes A, Smok G, Quiroz J et al. Functional studies in 408 patients with Barrett's esophagus, compared to 174 cases with intestinal metaplasia of the cardia. Am J Gastroenterol 2002; 97: 554-60.
55. Manifold D K, Marshall R E K, Anggiansah A, Owen W J. Effect of omeprazole on antral duodenogastric reflux in Barrett oesophagus. Scand J Gastroenterol 2000; 8: 796-801.
56. Parrilla P, Martinez de Haro L F, Ortiz A et al. Results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2003; 237: 291-8.
57. Watson D I, Pike G K, Baigrie R J et al. Prospective double-blind randomized trial of laparoscopic Nissen fundoplication with division and without division of short gastric vessels. Ann Surg 1997; 226: 642-52.
58. Wetscher G J, Profanter C, Gadenstatter M, Perdikis G, Glaser K, Hinder R A. Medical treatment of gastroesophageal reflux disease does not prevent the development of Barrett's metaplasia and poor esophageal body motility. Langenbecks Arch Surg 1997; 382: 95-9.
59. Isolauri J, Luostarinen M, Isolauri E, Reinikainen P, Viljakka M, Keyrilainen O. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92: 37-41.
60. Csendes A, Braghetto I, Burdiles P et al. Long-term results of classic antireflux surgery in 152 patients with Barrett's esophagus: Clinical, radiologic, endoscopic, manometric, and acid reflux test analysis before and late after operation. Surgery 1998; 123: 645-57.
61. Hofsetter W L, Peters J H, Demeester T R, Hagen J A, Demeester S R, Crookes P F. Long-term outcome of anti-reflux surgery in patients with Barrett's esophagus. Ann Surg 2001; 234: 532-9.
62. Gatenby P A C, Caygill C P J, Ramus J R et al. Esophagus (CLE): An underestimated cancer risk? A large cohort study of the relationship between Barrett's CLE segment length and adenocarcinoma risk. Eur J Gastroenterol Hepatol 2007; 19: 969-75.
63. Spechler S J, Lee E, Ahnen D et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease. JAMA 2001; 285: 2331-8.
64. Bonatti H, Bammer T, Achem S R et al.. Use of acid suppressive medications after laparoscopic antireflux surgery: Prevalence and clinical indications. Dig Dis Sci 2007; 52: 267-72.
65. Bammer T, Hinder R A, Klaus A, Trastek V F, Achem S R. Rationale for surgical therapy of Barrett's esophagus. Mayo Clin Proc 2001; 76: 335-42.
66. Corey K E, Schmitz S M, Shaheen N J. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol 2003; 98: 2390-4.